TH-004(Bangentai Biomedical)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTH-004(Bangentai Biomedical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLymphoma, T-CellHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Bangentai Biomedical Tech Group Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A